JOHN VIERLING to Biomarkers
This is a "connection" page, showing publications JOHN VIERLING has written about Biomarkers.
Connection Strength
0.218
-
Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis. Dig Dis Sci. 2018 03; 63(3):665-675.
Score: 0.069
-
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Aliment Pharmacol Ther. 2024 01; 59(2):186-200.
Score: 0.026
-
Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2021 06; 19(6):1248-1257.
Score: 0.021
-
Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature. J Autoimmun. 2019 07; 101:26-34.
Score: 0.019
-
Autoimmune hepatitis. Nat Rev Dis Primers. 2018 04 12; 4:18017.
Score: 0.018
-
Unmet needs and new models for future trials in autoimmune hepatitis. Lancet Gastroenterol Hepatol. 2018 05; 3(5):363-370.
Score: 0.018
-
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection. Ann Hepatol. 2016 Nov-Dec 2016; 15(6):834-845.
Score: 0.016
-
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology. 2014 Aug; 147(2):366-76.e6.
Score: 0.013
-
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio. Mol Genet Metab. 2013 Dec; 110(4):446-53.
Score: 0.013
-
Limited role for CXC chemokines in the pathogenesis of alpha-naphthylisothiocyanate-induced liver injury. Am J Physiol Gastrointest Liver Physiol. 2004 Sep; 287(3):G734-41.
Score: 0.007